Laura Calabresi, Italy
Università degli Studi di Milano Dipartimento di Scienze Farmacologiche e Biomolecolari
Moderator of 1 Session
Session Time
12:00 - 13:00
Session Evaluation
Option 1
[{"name":"Monogenic versus polygenic familial hypercholesterolemia: genetic risk score and response to treatment.","mode":"playlist","public":true,"info":{"id":1341,"presentation":"Monogenic versus polygenic familial hypercholesterolemia: genetic risk score and response to treatment.","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Ilenia Minicocci, Italy","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/Ilenia Minicocci - EAS20 - 1341 - Monogenic versus polygenic familial hypercholesterolemia genetic risk score and response to treatment.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/Ilenia Minicocci - EAS20 - 1341 - Monogenic versus polygenic familial hypercholesterolemia genetic risk score and response to treatment.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/46EF09E8.jpg","data":[],"tracks":[]}]},{"name":"Over 30 years of elaborate experience in LDL apheresis: an effective and well-tolerated treatment option for specific patient subgroups","mode":"playlist","public":true,"info":{"id":1319,"presentation":"Over 30 years of elaborate experience in LDL apheresis: an effective and well-tolerated treatment option for specific patient subgroups","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Klaus G. Parhofer, Germany","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/Klaus Parhofer - EAS20 - 1319 - Over 30 years of elaborate experience in LDL apheresis an effective and well-tolerated treatment option for specific patient subgro.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/Klaus Parhofer - EAS20 - 1319 - Over 30 years of elaborate experience in LDL apheresis an effective and well-tolerated treatment option for specific patient subgro.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/959AE9AF.jpg","data":[],"tracks":[]}]},{"name":"Antibodies against the c-terminus of apolipoprotein A-1 as predictors of death in the general population but not as therapeutic targets actionable through cognate peptides immunomodulation.","mode":"playlist","public":true,"info":{"id":673,"presentation":"Antibodies against the c-terminus of apolipoprotein A-1 as predictors of death in the general population but not as therapeutic targets actionable through cognate peptides immunomodulation.","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Nicolas Vuilleumier, Switzerland","photo":""},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/Nicolas Vuilleumier - EAS20 - 673 - Antibodies against the c-terminus of apolipoprotein A-1 as predictors of death in the general population but not as therapeutic targets actionable through cog.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/Nicolas Vuilleumier - EAS20 - 673 - Antibodies against the c-terminus of apolipoprotein A-1 as predictors of death in the general population but not as therapeutic targets actionable through cog.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/A7857560.jpg","data":[],"tracks":[]}]},{"name":"High plasma lipoprotein(a) levels are associated with increased prevalence of cardiovascular disease and poorer metabolic control in patients with type 1 diabetes mellitus","mode":"playlist","public":true,"info":{"id":879,"presentation":"High plasma lipoprotein(a) levels are associated with increased prevalence of cardiovascular disease and poorer metabolic control in patients with type 1 diabetes mellitus","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Karin Littmann, Sweden","photo":""},"playlist":[{"name":"High plasma lipoprotein(a) levels are associated with increased prevalence of cardiovascular disease","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/EAS20879.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/EAS20879.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/F7BDDE7C.jpg","data":[],"tracks":[]}]},{"name":"Live Q&A","mode":"playlist","public":true,"info":{"id":1678,"presentation":"Live Q&A","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Laura Calabresi, Italy, Ilenia Minicocci, Italy, Anna Theresa Ull, Germany, Nicolas Vuilleumier, Switzerland, Karin Littmann, Sweden","photo":""},"playlist":[{"name":"Rapid fire Session 3","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/Rapid fire Session 3.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/Rapid fire Session 3.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/D110C19D.jpg","data":[],"tracks":[]}]}]
{"type":2,"code":"7E32Xi03L"}
[session]
[presentation]
[presenter]
Presenter of 1 Presentation
Live Q&A
Session Time
12:00 - 13:00
Lecture Time
12:20 - 12:35
[{"name":"Live Q&A","mode":"playlist","public":true,"info":{"id":1678,"presentation":"Live Q&A","session":"Rapid fire Session #3 - Genetics and Epidemiology of Dyslipidemia","presenter":"Laura Calabresi, Italy, Ilenia Minicocci, Italy, Anna Theresa Ull, Germany, Nicolas Vuilleumier, Switzerland, Karin Littmann, Sweden","photo":""},"playlist":[{"name":"Rapid fire Session 3","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/Rapid fire Session 3.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/160\/Rapid fire Session 3.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/160\/D110C19D.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"9E22Xi0uW"}
[session]
[presentation]
[presenter]
Hide